172 related articles for article (PubMed ID: 10556807)
1. Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma.
Gould HJ; Mackay GA; Karagiannis SN; O'Toole CM; Marsh PJ; Daniel BE; Coney LR; Zurawski VR; Joseph M; Capron M; Gilbert M; Murphy GF; Korngold R
Eur J Immunol; 1999 Nov; 29(11):3527-37. PubMed ID: 10556807
[TBL] [Abstract][Full Text] [Related]
2. Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells.
Karagiannis SN; Wang Q; East N; Burke F; Riffard S; Bracher MG; Thompson RG; Durham SR; Schwartz LB; Balkwill FR; Gould HJ
Eur J Immunol; 2003 Apr; 33(4):1030-40. PubMed ID: 12672069
[TBL] [Abstract][Full Text] [Related]
3. Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity.
Rudman SM; Josephs DH; Cambrook H; Karagiannis P; Gilbert AE; Dodev T; Hunt J; Koers A; Montes A; Taams L; Canevari S; Figini M; Blower PJ; Beavil AJ; Nicodemus CF; Corrigan C; Kaye SB; Nestle FO; Gould HJ; Spicer JF; Karagiannis SN
Clin Exp Allergy; 2011 Oct; 41(10):1400-13. PubMed ID: 21569129
[TBL] [Abstract][Full Text] [Related]
4. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing.
Coney LR; Mezzanzanica D; Sanborn D; Casalini P; Colnaghi MI; Zurawski VR
Cancer Res; 1994 May; 54(9):2448-55. PubMed ID: 7512887
[TBL] [Abstract][Full Text] [Related]
5. IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells.
Karagiannis SN; Bracher MG; Hunt J; McCloskey N; Beavil RL; Beavil AJ; Fear DJ; Thompson RG; East N; Burke F; Moore RJ; Dombrowicz DD; Balkwill FR; Gould HJ
J Immunol; 2007 Sep; 179(5):2832-43. PubMed ID: 17709497
[TBL] [Abstract][Full Text] [Related]
6. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients.
Luiten RM; Warnaar SO; Sanborn D; Lamers CH; Bolhuis RL; Litvinov SV; Zurawski VR; Coney LR
J Immunother; 1997 Nov; 20(6):496-504. PubMed ID: 9409456
[TBL] [Abstract][Full Text] [Related]
7. Three-colour flow cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosis.
Bracher M; Gould HJ; Sutton BJ; Dombrowicz D; Karagiannis SN
J Immunol Methods; 2007 Jun; 323(2):160-71. PubMed ID: 17531261
[TBL] [Abstract][Full Text] [Related]
8. Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic.
Mezzanzanica D; Canevari S; Colnaghi MI
Int J Clin Lab Res; 1991; 21(2):159-64. PubMed ID: 1815760
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha.
Ebel W; Routhier EL; Foley B; Jacob S; McDonough JM; Patel RK; Turchin HA; Chao Q; Kline JB; Old LJ; Phillips MD; Nicolaides NC; Sass PM; Grasso L
Cancer Immun; 2007 Mar; 7():6. PubMed ID: 17346028
[TBL] [Abstract][Full Text] [Related]
10. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein.
Coney LR; Tomassetti A; Carayannopoulos L; Frasca V; Kamen BA; Colnaghi MI; Zurawski VR
Cancer Res; 1991 Nov; 51(22):6125-32. PubMed ID: 1840502
[TBL] [Abstract][Full Text] [Related]
11. Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18.
Andersson H; Lindegren S; Back T; Jacobsson L; Leser G; Horvath G
Anticancer Res; 2000; 20(1A):459-62. PubMed ID: 10769696
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific IgE-mediated inhibition of human colorectal carcinoma xenograft growth.
Kershaw MH; Darcy PK; Trapani JA; MacGregor D; Smyth MJ
Oncol Res; 1998; 10(3):133-42. PubMed ID: 9700724
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers.
Suzuki M; Kato-Nakano M; Kawamoto S; Furuya A; Abe Y; Misaka H; Kimoto N; Nakamura K; Ohta S; Ando H
Cancer Sci; 2009 Sep; 100(9):1623-30. PubMed ID: 19555390
[TBL] [Abstract][Full Text] [Related]
14. Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody, MOv18, reactive with an ovarian cancer-associated antigen.
Molthoff CF; Buist MR; Kenemans P; Pinedo HM; Boven E
J Nucl Med; 1992 Nov; 33(11):2000-5. PubMed ID: 1432162
[TBL] [Abstract][Full Text] [Related]
15. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
16. A novel antibody-like TCRγδ-Ig fusion protein exhibits antitumor activity against human ovarian carcinoma.
Zheng J; Guo Y; Ji X; Cui L; He W
Cancer Lett; 2013 Dec; 341(2):150-8. PubMed ID: 23920126
[TBL] [Abstract][Full Text] [Related]
17. A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells.
Miyamoto S; Iwamoto R; Furuya A; Takahashi K; Sasaki Y; Ando H; Yotsumoto F; Yoneda T; Hamaoka M; Yagi H; Murakami T; Hori S; Shitara K; Mekada E
Clin Cancer Res; 2011 Nov; 17(21):6733-41. PubMed ID: 21918176
[TBL] [Abstract][Full Text] [Related]
18. Unidirectional potentiation of binding between two anti-FBP MAbs: evaluation of the involved mechanisms.
Casalini P; Mezzanzanica D; Valota O; Adobati E; Tomassetti A; Colnaghi MI; Canevari S
J Cell Biochem; 1995 May; 58(1):47-55. PubMed ID: 7642722
[TBL] [Abstract][Full Text] [Related]
19. Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells.
Karagiannis SN; Bracher MG; Beavil RL; Beavil AJ; Hunt J; McCloskey N; Thompson RG; East N; Burke F; Sutton BJ; Dombrowicz D; Balkwill FR; Gould HJ
Cancer Immunol Immunother; 2008 Feb; 57(2):247-63. PubMed ID: 17657488
[TBL] [Abstract][Full Text] [Related]
20. Suppression of mast cell degranulation through a dual-targeting tandem IgE-IgG Fc domain biologic engineered to bind with high affinity to FcγRIIb.
Cemerski S; Chu SY; Moore GL; Muchhal US; Desjarlais JR; Szymkowski DE
Immunol Lett; 2012 Mar; 143(1):34-43. PubMed ID: 22305932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
